Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven H Bernstein

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Seminars in Oncology|February 1, 2017
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Seminars in Oncology|February 14, 2002
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Frontiers in Immunology|August 21, 2018
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung CancerNataly Manjarrez-Orduño, Laurence C Menard, Selena Kansal, et al.
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Seminars in Oncology|February 1, 2017
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Seminars in Oncology|February 14, 2002
Rituximab in combination with CHOP or fludarabine in low-grade lymphomaMyron S Czuczman, Alexandra Fallon, Alice Mohr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2006
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphomaRichard I Fisher, Steven H Bernstein, Brad S Kahl, et al.
Frontiers in Immunology|August 21, 2018
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung CancerNataly Manjarrez-Orduño, Laurence C Menard, Selena Kansal, et al.
Blood|July 13, 2014
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphomaPaul M Barr, Thomas P Miller, Jonathan W Friedberg, et al.
British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Pageof 6